

A discovery and IP development company, advancing the science behind medical cannabis



Stock Info

Canada	CSE:VRT
U.S	OTC:VRTHF
Germany	FRT:2VP
Shares Outstanding	36.99M*
Market Capitalization	19.9M
Fiscal Year End	April 30th

*6/3/2017

2017 News Highlights

- Health Canada Final Review Notification Received for ACMPR Application
- Veritas-Cannevert Commences Preparation of First Clinical Trials of Cannabis Targeting Pain
- Veritas Pharma Enters into Agreement to Secure ACMPR License and Cannabis Growing Facility
- Veritas Pharma Inc. Exclusive Partner Qualifies For Non-Dilutive Grant – Update

Investor Relations

Contact: Sam Eskandri
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Web: veritaspharmainc.com

About Veritas Pharma

- Solving the critical need for real science to support claims surrounding medical marijuana, developing the most effective proprietary and patented cultivars (strains) targeting pain and nausea related to cancer.
- Research and commercialization led by strong management and renowned group of scientists with a low cost research and development model to help drive shareholder value
- Established exclusive partner alliance and investment in high-level R&D arm, Cannevert Therapeutics, bringing together veteran academic pharmacologists, anesthetists & chemists
- Has already progressed from Chemical and Biological (animal testing) assays to clinical trials for pain
- Clinical trials to demonstrate real therapeutic utilities, with the potential to deliver the industry's first set of standards providing doctors with necessary evidence to confidently recommend Veritas' proprietary strains
- Speed-to-market employs a whole plant methodology, translating to years faster to market, estimated at one-tenth the time of traditional pharma drug approval
- Veritas (Through its exclusive option to purchase 100% ownership of Sechelt) is in Final Review stage of being granted ACMPR license by Health Canada

Multi - Billion Dollar Growth Industry

- The medical marijuana market is US\$1.47 billion in North America alone¹
- Forecast 17% annual growth, with market estimated to double in size within 5 years²
- Canada has a national medical cannabis program and is currently progressing towards legalization of marijuana for recreational use
- 39 states have legalized cannabis in some form for recreational or medicinal use in the US so far

Major Growth Drivers

- Easing regulatory framework and continuing trend towards liberalization of cannabis laws at the national and state levels will help drive the market
- Future innovation and advancement in science related to cannabis therapeutics will accelerate patient adoption and consumption
- Opportunity exists to create new distinguishable products that are clinically tested, supported by real data to be sold or licensed to various markets for medicinal use
- Growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as cannabis. The global opioids market is valued at a staggering US\$34.8bn in 2015³

Leading Management

Dr. Lui Franciosi, PhD – CEO

20+ years experience conducting pharmaceutical and medical device studies in academia and industry. Previously, Chief Operating Officer of Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior, he completed his post-doctoral research in COPD progression modelling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. Obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada — and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.

David Alexander, CPA /CA – CFO

Holds a BComm in Finance from The University of British Columbia. Past achievements include; CFO of Arakis Energy Corporation, an international oil and gas development company, and managed the company's growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company (Nasdaq: CRME).

Linda Sampson

Ms. Sampson is an international marketing and sales professional, having practiced in South Africa, Europe, the US and Canada. She brings a dynamic energy, a wealth of talent, and a multi-layered business expertise to the Company. She is a business start-up professional, with a history of ground-up to successful ventures. An accomplished sales professional, marketer, designer, developer with international experience, she brings superior business branding skills and internal administration expertise to Veritas. Ms. Sampson is currently President of Marapharm Ventures Inc. Marapharm is a developmental stage publicly traded medical marijuana company with operations based in British Columbia; Nevada and Washington in the United States.

Donald R. Carlow, MD – Director

Past President and CEO (Jan 1994–Oct 2000) of the British Columbia Cancer Agency (BCCA). Dr. Carlow's efforts led to the development of new cancer centers, as well as laying the groundwork for the BC Cancer Research Center. Dr. Carlow was a member of the board of the Vancouver Island Health Authority, where he chaired the board's health quality committee for four years. He proposed the establishment of the BC Council on Quality and Safety. Dr. Carlow was also a judge for the 3M National Health Care Quality Awards for four years during the 90's.

Veritas Clinical Cannabis Development Pipelined

- Chronic Pain (Cancer Pain)
- Nausea & Vomiting
- Inflammation
- Muscle Spasms
- Epilepsy
- Post Traumatic Stress Disorder (PTSD)

Confidence in Highly Credentialed Team of Scientists



- **Dr. Michael J.A. Walker, PhD**
- **Dr. Bernard A. MacLeod, MD**
- **Dr. Richard A. Wall, PhD**
- **Dr. Ernest Puil, PhD**
- **Dr. Andrew Hegle, PhD**
- **Dr. Thomas Stokes, PhD**
- **Dr. Ricardo Rivera-Acevedo, PhD**



"The strategic alliance that we've formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique

strains of medicinal cannabis. These plants will be patent protected for a variety of unmet medical needs. These scientists have indeed the rare skills necessary to make blockbuster medicines, with a history of generating over \$1 billion worth of investor value based on previous drug discoveries."

-Dr. Franciosi, PhD - CEO